Form 4: Teleflex CEO Jason Weidman Receives Equity Grant

Teleflex Incorporated CEO Jason R. Weidman was granted 53,983 restricted stock units and 26,071 stock options.

Summary

• CEO Jason R. Weidman received an equity compensation package on June 8, 2026.
• The grant includes 53,983 restricted stock units (RSUs) vesting in four equal annual installments starting June 8, 2027.
• The grant also includes 26,071 stock options with an exercise price of $131.74, vesting in three equal annual installments starting June 8, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

• Alignment of executive interests with long-term shareholder value through multi-year vesting schedules.

Negatives

• Dilutive impact of new equity issuance on existing shareholders.

Risks

• Vesting is contingent upon the reporting person's continuous service to the issuer.

Future Outlook

The equity grants are subject to continuous service requirements, incentivizing the CEO to remain with the company through at least 2030.

Industry Context

StockSavvy.ai notes that standard executive compensation packages in the medical device sector frequently utilize a mix of RSUs and options to balance retention and performance incentives.

Comparison to Industry Standards

• The use of 3-4 year vesting schedules is consistent with standard corporate governance practices for S&P 500 companies.
• The mix of time-based RSUs and options is typical for CEO compensation structures in the healthcare equipment industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new shares upon vesting.

Next Steps

• Vesting of initial tranches of equity on June 8, 2027.

Key Dates

Keywords

Teleflex, TFX, Insider Trading, Executive Compensation, Form 4, Equity Grant